Dossier assessment
Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
In addition to standard therapies for prophylaxis of ischaemic cardiovascular events in adult patients with atherosclerotic coronary artery disease and a recent myocardial infarction
Hint of a non-quantifiable added benefit
Additional information
Federal Joint Committee (G-BA)
20-08-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-16
- Commission
- Commission awarded on 27.02.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-16
Connected Projects
-
Addendum
Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction) – Addendum to Project A26-16
Status: Commission completed